Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Conditions:   Condylomata Acuminata;   Cervical Cancer Interventions:   Biological: HPV Vaccine,270μg/1.0ml;   Biological: Placebo Sponsors:   Xiamen University;   Xiamen Innovax Biotech Co., Ltd;   Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials